Hologic Announces Preliminary Revenue Results for Second Quarter of Fiscal 2020, Withdraws 2020 Financial Guidance due to COVID-19 Pandemic - Seite 2

(6.1)%

(5.5)%

Medical Aesthetics*

$0

$73.8

NA

NA

GYN Surgical

$105.4

$102.2

3.1%

3.6%

Skeletal Health

$23.7

$24.2

(2.1)%

(1.6%)

Total

$756.1

$818.4

(7.6)%

(7.1%)

Excluding Blood, SSI, Aesthetics

$735.1

$731.2

0.5%

1.1%

* Hologic completed the divestiture of its Cynosure medical aesthetics business on December 30, 2019.

Withdrawal of Financial Guidance

The COVID-19 pandemic and related economic disruption had a significant negative effect on Hologic’s business in late March. Most notably, sales of Breast Health products were weaker than expected as customers focused on responding to COVID-19, and restricted access to their facilities in order to limit the virus’s spread. In addition, sales of GYN Surgical and Diagnostics products were hurt by the deferral of elective procedures and physician office visits. These lower-than-expected revenues are expected to negatively affect gross margin in the second quarter, resulting in earnings per share (EPS) below the Company’s prior expectations.

Hologic expects these factors to continue to have a significant negative impact on its future revenue, especially in the third quarter of fiscal 2020. As a result, the Company is implementing a number of measures to reduce expenses across the organization. However, because the scope and duration of the COVID-19 pandemic are uncertain, the Company cannot currently quantify the net financial effect of these factors. The Company is therefore withdrawing its financial guidance for the second quarter and full year 2020, which was provided on January 29, 2020.